Pharma Market Entry Strategies
Sequence, model and access readiness.
How pharma teams design country market entry — sequencing, partner / direct / hybrid models and access readiness.
"How and where do we enter — and in what sequence?"
Market entry is three intertwined decisions: which countries first, which model (direct / partner / hybrid) per country, and what access readiness is required.
Market entry is the most leveraged set of pre-launch decisions. Sequence, model and access readiness — interconnected — define realized launch revenue.
What we’re seeing in the data.
Sequence > simultaneous launch
Rarely launch everywhere at once.
Model varies by country
Direct in core; partner in long tail.
Access readiness gates entry
Without access, launch is theatre.
How to think about it.
-
01
Score country priority
TAM × access × competition.
-
02
Choose entry model
Direct / partner / hybrid.
-
03
Plan access readiness
Evidence, MEA, dossier.
-
04
Sequence launch
Country-by-country plan.
What separates a good answer from a defensible one.
Don’t over-extend.
Country sequence affects EU prices.
Bridge between approval and reimbursement.
Where the signal comes from.
Common questions.
Direct or partner?
Direct in core 5–10 markets; partner / distributor in tail.
Sequence horizon?
12–36 months; longer for complex therapies.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist